Plus Intangible Assets vs Net Receivables Analysis

PSTV Stock

USD 0.74 0.15 25.42%

Plus Therapeutics financial indicator trend analysis is much more than just breaking down Plus Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Plus Therapeutics is a good investment. Please check the relationship between Plus Therapeutics Intangible Assets and its Net Receivables accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Plus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.

Intangible Assets vs Net Receivables

Intangible Assets vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Plus Therapeutics Intangible Assets account and Net Receivables. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Plus Therapeutics' Intangible Assets and Net Receivables is 0.49. Overlapping area represents the amount of variation of Intangible Assets that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Plus Therapeutics, assuming nothing else is changed. The correlation between historical values of Plus Therapeutics' Intangible Assets and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Intangible Assets of Plus Therapeutics are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Intangible Assets i.e., Plus Therapeutics' Intangible Assets and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.49

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Intangible Assets

Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.

Net Receivables

Most indicators from Plus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Plus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Plus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.At this time, Plus Therapeutics' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 8.6 M in 2025, despite the fact that Discontinued Operations is likely to grow to (6.5 M).

Plus Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Net Debt	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Retained Earnings	Non Currrent Assets Other	Net Receivables	Short Term Investments	Inventory	Other Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Accounts Payable
Total Assets		0.92	0.57	0.12	0.82	0.73	0.25	0.8	0.48	0.86	0.01	0.83	0.91	0.38	0.28	-0.05	0.18	0.33	0.64	-0.5	0.73	0.08	0.36	0.59	0.34	0.42
Short Long Term Debt Total	0.92		0.35	0.4	0.68	0.73	0.3	0.67	0.7	0.85	-0.11	0.87	0.8	0.3	0.4	-0.04	0.27	0.4	0.78	-0.41	0.75	-0.05	0.55	0.57	0.2	0.35
Total Stockholder Equity	0.57	0.35		-0.26	0.54	0.43	0.23	0.49	-0.24	0.2	0.11	0.03	0.51	-0.03	-0.18	0.35	0.14	0.23	0.06	-0.22	0.34	0.37	0.11	0.27	0.2	0.12
Net Debt	0.12	0.4	-0.26		-0.4	0.63	0.45	-0.41	0.62	0.09	-0.19	0.32	-0.22	0.3	0.57	-0.11	0.13	0.49	0.31	0.01	0.45	-0.05	0.54	0.23	-0.44	0.01
Cash	0.82	0.68	0.54	-0.4		0.22	-0.06	0.99	0.21	0.76	0.03	0.62	0.97	0.05	-0.04	0.04	0.16	0.01	0.54	-0.42	0.37	-0.02	0.13	0.35	0.56	0.34
Non Current Assets Total	0.73	0.73	0.43	0.63	0.22		0.53	0.18	0.49	0.52	0.0	0.59	0.37	0.58	0.43	0.0	0.15	0.57	0.36	-0.33	0.79	0.21	0.45	0.56	-0.07	0.27
Other Assets	0.25	0.3	0.23	0.45	-0.06	0.53		-0.09	0.03	0.03	0.0	0.14	0.01	0.09	0.36	0.19	0.08	0.99	-0.01	-0.1	0.11	0.62	0.48	0.06	0.01	0.07
Cash And Short Term Investments	0.8	0.67	0.49	-0.41	0.99	0.18	-0.09		0.21	0.77	0.04	0.64	0.98	0.04	-0.02	-0.03	0.13	-0.02	0.55	-0.44	0.35	-0.06	0.11	0.34	0.58	0.38
Common Stock Shares Outstanding	0.48	0.7	-0.24	0.62	0.21	0.49	0.03	0.21		0.62	-0.19	0.71	0.35	0.35	0.42	-0.24	0.21	0.13	0.69	-0.16	0.57	-0.22	0.41	0.36	-0.19	0.15
Non Current Liabilities Total	0.86	0.85	0.2	0.09	0.76	0.52	0.03	0.77	0.62		-0.24	0.89	0.84	0.49	0.05	-0.18	0.36	0.1	0.72	-0.27	0.73	-0.23	0.08	0.64	0.5	0.22
Other Stockholder Equity	0.01	-0.11	0.11	-0.19	0.03	0.0	0.0	0.04	-0.19	-0.24		-0.1	0.02	-0.03	0.38	-0.34	-0.9	0.02	-0.36	-0.77	-0.41	0.33	0.12	-0.14	-0.42	0.77
Total Liab	0.83	0.87	0.03	0.32	0.62	0.59	0.14	0.64	0.71	0.89	-0.1		0.76	0.47	0.46	-0.34	0.1	0.24	0.74	-0.48	0.64	-0.17	0.36	0.53	0.28	0.46
Total Current Assets	0.91	0.8	0.51	-0.22	0.97	0.37	0.01	0.98	0.35	0.84	0.02	0.76		0.15	0.11	-0.07	0.16	0.09	0.65	-0.47	0.5	-0.03	0.21	0.45	0.51	0.41
Other Current Liab	0.38	0.3	-0.03	0.3	0.05	0.58	0.09	0.04	0.35	0.49	-0.03	0.47	0.15		0.08	-0.3	0.06	0.11	0.23	-0.17	0.49	-0.09	-0.24	0.39	0.12	0.15
Total Current Liabilities	0.28	0.4	-0.18	0.57	-0.04	0.43	0.36	-0.02	0.42	0.05	0.38	0.46	0.11	0.08		-0.25	-0.45	0.44	0.26	-0.57	0.07	0.21	0.77	-0.07	-0.39	0.6
Property Plant And Equipment Net	-0.05	-0.04	0.35	-0.11	0.04	0.0	0.19	-0.03	-0.24	-0.18	-0.34	-0.34	-0.07	-0.3	-0.25		0.52	0.13	-0.17	0.48	0.06	0.17	0.24	-0.14	0.1	-0.56
Retained Earnings	0.18	0.27	0.14	0.13	0.16	0.15	0.08	0.13	0.21	0.36	-0.9	0.1	0.16	0.06	-0.45	0.52		0.07	0.4	0.74	0.55	-0.21	-0.08	0.24	0.48	-0.79
Non Currrent Assets Other	0.33	0.4	0.23	0.49	0.01	0.57	0.99	-0.02	0.13	0.1	0.02	0.24	0.09	0.11	0.44	0.13	0.07		0.12	-0.18	0.15	0.6	0.54	0.08	-0.01	0.14
Net Receivables	0.64	0.78	0.06	0.31	0.54	0.36	-0.01	0.55	0.69	0.72	-0.36	0.74	0.65	0.23	0.26	-0.17	0.4	0.12		-0.13	0.54	-0.27	0.32	0.37	0.23	0.11
Short Term Investments	-0.5	-0.41	-0.22	0.01	-0.42	-0.33	-0.1	-0.44	-0.16	-0.27	-0.77	-0.48	-0.47	-0.17	-0.57	0.48	0.74	-0.18	-0.13		0.02	-0.17	-0.36	-0.16	0.17	-0.99
Inventory	0.73	0.75	0.34	0.45	0.37	0.79	0.11	0.35	0.57	0.73	-0.41	0.64	0.5	0.49	0.07	0.06	0.55	0.15	0.54	0.02		-0.2	0.19	0.69	0.23	-0.08
Other Current Assets	0.08	-0.05	0.37	-0.05	-0.02	0.21	0.62	-0.06	-0.22	-0.23	0.33	-0.17	-0.03	-0.09	0.21	0.17	-0.21	0.6	-0.27	-0.17	-0.2		0.16	-0.01	-0.22	0.12
Short Term Debt	0.36	0.55	0.11	0.54	0.13	0.45	0.48	0.11	0.41	0.08	0.12	0.36	0.21	-0.24	0.77	0.24	-0.08	0.54	0.32	-0.36	0.19	0.16		-0.09	-0.3	0.32
Common Stock	0.59	0.57	0.27	0.23	0.35	0.56	0.06	0.34	0.36	0.64	-0.14	0.53	0.45	0.39	-0.07	-0.14	0.24	0.08	0.37	-0.16	0.69	-0.01	-0.09		0.06	0.12
Current Deferred Revenue	0.34	0.2	0.2	-0.44	0.56	-0.07	0.01	0.58	-0.19	0.5	-0.42	0.28	0.51	0.12	-0.39	0.1	0.48	-0.01	0.23	0.17	0.23	-0.22	-0.3	0.06		-0.19
Accounts Payable	0.42	0.35	0.12	0.01	0.34	0.27	0.07	0.38	0.15	0.22	0.77	0.46	0.41	0.15	0.6	-0.56	-0.79	0.14	0.11	-0.99	-0.08	0.12	0.32	0.12	-0.19

Click cells to compare fundamentals

Plus Therapeutics Account Relationship Matchups

Plus Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	12.1M	22.0M	23.9M	11.4M	6.6M	6.3M
Short Long Term Debt Total	7.0M	7.0M	5.6M	4.2M	3.4M	3.2M
Total Stockholder Equity	3.0M	10.8M	6.4M	(1.3M)	(8.9M)	(8.5M)
Net Debt	(1.4M)	(11.4M)	(12.5M)	(4.4M)	3.3M	3.5M
Cash	8.3M	18.4M	18.1M	8.6M	76K	72.2K
Non Current Assets Total	2.9M	2.3M	2.1M	1.6M	1.4M	1.3M
Other Assets	72K	652K	16K	12K	10.8K	10.3K
Cash And Short Term Investments	8.3M	18.4M	18.1M	8.6M	3.6M	3.4M
Common Stock Shares Outstanding	295.2K	805.9K	1.8M	3.1M	7.7M	9.7M
Liabilities And Stockholders Equity	12.1M	22.0M	23.9M	11.4M	6.6M	6.3M
Non Current Liabilities Total	535K	5.3M	5.6M	2.0M	31K	29.5K
Other Stockholder Equity	436.5M	457.7M	473.6M	479.1M	484.5M	249.2M
Total Liab	9.1M	11.1M	17.4M	12.7M	15.6M	24.5M
Total Current Assets	9.2M	19.7M	21.8M	9.8M	5.3M	5.0M
Other Current Liab	1.3M	1.4M	1.7M	1.9M	2.7M	2.6M
Total Current Liabilities	8.5M	5.9M	11.9M	10.7M	15.6M	14.8M
Property Plant And Equipment Net	2.5M	1.8M	1.6M	1.1M	521K	495.0K
Retained Earnings	(433.5M)	(446.9M)	(467.2M)	(480.5M)	(493.5M)	(468.8M)
Non Currrent Assets Other	11.7M	72K	16K	12K	32K	11.4K
Net Receivables	1.3M	59K	7K	571K	513.9K	1.0M
Other Current Assets	770K	1.3M	3.7M	1.3M	436K	414.2K
Short Term Debt	6.5M	1.8M	1.8M	4.1M	3.3M	5.4M
Common Stock	4K	7K	16K	34K	5K	5.7K
Current Deferred Revenue	1.9M	2.9M	1.3M	141K	126.9K	120.6K
Accounts Payable	789K	2.6M	8.4M	4.8M	9.5M	9.9M
Property Plant And Equipment Gross	2.5M	1.8M	1.6M	3.6M	3.7M	2.1M
Net Tangible Assets	788K	2.6M	10.4M	6.0M	6.9M	3.8M
Property Plant Equipment	2.2M	1.8M	1.8M	1.6M	1.8M	2.0M
Other Liab	6.9M	7K	1K	1.6M	1.9M	1.4M
Capital Lease Obligations	661K	380K	251K	205K	75K	71.3K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Plus Stock Analysis

When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC